Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
Nalbuphine Hydrochloride in Idiopathic Pulmonary Fibrosis: NCT07671911 Clinical Landscape Report 2026
9 min read
Nalbuphine Hydrochloride in Idiopathic Pulmonary Fibrosis: NCT07671911 Clinical Landscape Report 2026
11 September 2026
NCT07671911 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
VTRU-200 in High Risk Myelodysplastic Syndrome: NCT07749976 Clinical Landscape Report 2026
9 min read
VTRU-200 in High Risk Myelodysplastic Syndrome: NCT07749976 Clinical Landscape Report 2026
11 September 2026
NCT07749976 clinical landscape for High Risk Myelodysplastic Syndrome: endpoints, sponsor, phase, geography, readouts, asset context and development white sp…
Read →
R01 in Advanced Lung Squamous Cell Carcinoma: NCT07806500 Clinical Landscape Report 2026
9 min read
R01 in Advanced Lung Squamous Cell Carcinoma: NCT07806500 Clinical Landscape Report 2026
11 September 2026
NCT07806500 clinical landscape for Advanced Lung Squamous Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white…
Read →
CT-179 in Recurrent Glioblastoma: NCT07739017 Clinical Landscape Report 2026
9 min read
CT-179 in Recurrent Glioblastoma: NCT07739017 Clinical Landscape Report 2026
11 September 2026
NCT07739017 clinical landscape for Recurrent Glioblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
MWN105 in Diabetes Mellitus, Type 2: NCT07801313 Clinical Landscape Report 2026
9 min read
MWN105 in Diabetes Mellitus, Type 2: NCT07801313 Clinical Landscape Report 2026
11 September 2026
NCT07801313 clinical landscape for Diabetes Mellitus, Type 2: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Gemcitabine Hydrochloride in Non-Muscle Invasive Bladder Neoplasms: NCT07747740 Clinical Landscape Report 2026
9 min read
Gemcitabine Hydrochloride in Non-Muscle Invasive Bladder Neoplasms: NCT07747740 Clinical Landscape Report 2026
11 September 2026
NCT07747740 clinical landscape for Non-Muscle Invasive Bladder Neoplasms: endpoints, sponsor, phase, geography, readouts, asset context and development white…
Read →
Dupilumab Biosimilar (Innovent Biologics) in Dermatitis, Atopic: NCT07754786 Clinical Landscape Report 2026
9 min read
Dupilumab Biosimilar (Innovent Biologics) in Dermatitis, Atopic: NCT07754786 Clinical Landscape Report 2026
11 September 2026
NCT07754786 clinical landscape for Dermatitis, Atopic: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
GB-0895 in Severe asthma: NCT07276724 Clinical Landscape Report 2026
9 min read
GB-0895 in Severe asthma: NCT07276724 Clinical Landscape Report 2026
11 September 2026
NCT07276724 clinical landscape for Severe asthma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Curcumin in Hemoglobin SC Disease: NCT07566494 Clinical Landscape Report 2026
9 min read
Curcumin in Hemoglobin SC Disease: NCT07566494 Clinical Landscape Report 2026
11 September 2026
NCT07566494 clinical landscape for Hemoglobin SC Disease: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
VIM-0423 in Young onset Parkinson disease: NCT07804615 Clinical Landscape Report 2026
9 min read
VIM-0423 in Young onset Parkinson disease: NCT07804615 Clinical Landscape Report 2026
11 September 2026
NCT07804615 clinical landscape for Young onset Parkinson disease: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Busulfan in Acute Myeloid Leukemia: NCT07762508 Clinical Landscape Report 2026
9 min read
Busulfan in Acute Myeloid Leukemia: NCT07762508 Clinical Landscape Report 2026
11 September 2026
NCT07762508 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
LX-101(Lirum Therapeutics) in Ewing Sarcoma: NCT07781891 Clinical Landscape Report 2026
9 min read
LX-101(Lirum Therapeutics) in Ewing Sarcoma: NCT07781891 Clinical Landscape Report 2026
11 September 2026
NCT07781891 clinical landscape for Ewing Sarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →